14Nov 2023
Aclaris Therapeutics Announces Disappointing Results in Phase 2b Trial of Zunsemetinib for Rheumatoid Arthritis

Aclaris Therapeutics Announces Disappointing Results in Phase 2b Trial of Zunsemetinib for Rheumatoid Arthritis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported that the Phase 2b study of zunsemetinib (ATI-450) did not meet its primary or secondary efficacy endpoints in patients with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202). The trial, involving 251 patients across three treatment arms, showed no significant differences in ACR20, ACR50, ACR70 responses, or DAS28-CRP between zunsemetinib and placebo at 12 weeks. No notable safety concerns were identified. Consequently, Aclaris will cease further development of the ATI-450 program, including halting the ongoing Phase 2a trial in psoriatic arthritis.

  • #family health

Like

Save

Share